November 11, 2019
Nippon Kayaku’s sales of biosimilars reached 2 billion yen in the April-September period, with its Remicade (infliximab) biosimilar gaining a 10% market share on a volume basis. Its sales are estimated to expand to 4.3 billion yen in the full...read more